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Abstract
Background: Matrix metalloproteinases (MMPs) are enzymes that degrade all the components of extra cellular
matrix and collagen. Various types of MMPs are known to be expressed and activated in patients with oral
submucous fibrosis (OSMF) as well as head and neck squamous cell carcinoma (HNSCC). The purpose of this study
was to asses the association of the single nucleotide polymorphism (SNP) adenosine insertion/deletion
polymorphism (-1171 5A->6A) in the MMP-3 promoter region in these lesions.
Methods: MMP-3 SNP was genotyped by polymerase chain reaction-restriction fragment polymorphism (PCR-RFLP)
analysis in a case control study consisting of 362 participants; 101 cases of OSMF, 135 of HNSCC and 126 controls,
compared for age, sex and habits. ROC distribution was plotted to assess the contributions of genetic variation in
MMP-3 genotypes with relation to age.
Results: Analysis of MMP 3 (-1171 5A->6A) polymorphism revealed the frequency of 5A allele in OSMF, HNSCC and
controls to be 0.15, 0.13 and 0.07, respectively. A significant difference was found in 5A genotype frequency
between OSMF (5A genotype frequency = 0.15, p = 0.01, OR = 2.26, 95% CI = 1.22-4.20) and in controls (5A
genotype frequency 0.07) as well as HNSCC (5A genotype frequency 0.13, p = 0.03,95%CI = 1.06-3.51) and controls
(5A genotype frequency = 0.07) In this study, 5A genotype had greater than two fold risk for developing OSMF
(OR = 2.26) and nearly the same in case of HNSCC (OR = 1.94) as compared to controls. In patients with OSMF as
well as HNSCC, the ROC analysis between the MMP-3 genotype and age, 6A/6A allele was found to be significant
in patients both over and under 45 years of age; while the 5A/5A carrier alleles showed an association only in
patients less than 45 years of age.
Conclusions: This study concluded that the expression of MMP-3 genotype associated with the 5A alleles, it may
have an important role in the susceptibility of the patients to develop OSMF and HNSCC.
Background
Matrix metalloproteinases (MMP) are a group of structu-
rally related zinc-dependent endopeptidases and have the
capability to degrade all components of extra cellular
matrix (ECM) [1]. MMPs are synthesized mainly by fibro-
blasts and to a lesser extent by activated macrophages and
keratinocytes adjacent to the sites of injury [2]. MMP-3,
also known as stromelysin-1, it is responsible for
degradation of collagen type IV [3]. Brinckerhoff et al
reported that MMP-3 also plays an important role in acti-
vation of proMMP-1 into the active form of MMP-1 in
malignant tissues [4]. MMP-3 expression is low in normal
tissues but it is altered during tumour formation, where
remodeling of the extra cellular matrix is required [5].
MMP-3 has wide substrate specificity for various ECM
components and is involved in many biological functions,
including extracellular matrix degradation and remodel-
ling, cell proliferation, angiogenesis as well as induction of
synthesis of other metalloproteinases such as MMP-1 and
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molecular functions and single nucleotide polymorphic
association of different MMPs such as MMP-1 (-1607 1G/
2G), MMP-2 (-1306 C/T), MMP-3 (-1171 5A/6A), MMP-
9 (-1562 C/T) and TIMP-2 (-418 G/C or C/C) and it’s
possible therapeutic aspects of these proteases and they
concluded that MMPs may play an association with poten-
tially malignant (OSMF) and malignant head and neck
lesions (HNSCC). Further research is required for the
development of their potential diagnostic and therapeutic
possibilities [7].
The expression of MMP-3 in carcinogenesis is regulated
primarily at the transcriptional level, but there is also evi-
dence of modulation of mRNA stability in response to
growth factors and cytokines secreted by tumour-infiltrating
inflammatory cells as well as by tumour and stromal cells
[3,5,8]. MMP-3 transcription is higher in head and neck
squamous cell carcinoma (HNSCC) and several other types
of malignancies including lung and breast carcinomas
[9-12]. MMP-3 degrades types II, V, IX and X collagens,
proteoglycans, gelatine, fibronectin, laminin and elastin
[13]. MMP-3 can also activate other MMPs, including col-
lagenase, matrilysin and gelatinase B.
The MMP-3 gene has been mapped to the long arm
of chromosome 11q22.3 and the level of expression of
this gene can be influenced by single nucleotide poly-
morphisms (SNPs) in the promoter region of their
respective gene [14]. The promoter region of MMP3 is
characterized by a 5A/6A promoter polymorphism at
position -1171 in which one allele has six adenosine
(6A) and the second has five adenosine (5A). A single
adenosine insertion/deletion polymorphism (5A/6A) at
position -1171 of the MMP-3 promoter region causes
different transcription of MMP-3.
In-vitro assays of promoter activity showed that the
5A allele had a two-fold higher promoter activity than
the 6A allele [15]. The 5A allele is more prevalent in
the European population (frequency range 40-50%) as
compared to East Asian population (frequency range 7-
20%) [11,14,16]. At position -1171 of the promoter
region of the MMP-3 gene, a polymorphism of 5 or 6
adenosines (5A/6A) affects its low transcription level.
The 5A allele results in higher gene expression in fibro-
blasts and vascular smooth muscle cells compared to
the 6A allele and the 6A allele has a lower promoter
reactivity than the 5A allele in vitro [14].
The aim of this study was to find out the association
of the -1171 5A->6A polymorphism in the MMP-3 gene
in patients suffering from OSMF, HNSCC and healthy
controls.
Methods
Patients with OSMF and HNSCC as well as controls
from the Departments of Otorhinolaryngology and
Pathology, Moti Lal Nehru Medical College, Allahabad,
India, were included in the study from June 2007 to
October 2009; this study was approved by the institu-
tional ethical committee. This case-control study group
included 362 participants. Two hundred and thirty six
subjects (average age 43.4 ± 14.8 years) were included in
this study, of which 101 patients suffered from OSMF
(78 males and 23 females) and 135 patients from
HNSCC (114 males and 21 females) and 126 healthy
subjects who did not have a history of pre-malignant or
malignant lesions. These (average age 37.01 ± 12.89
years, 105 males 21 females) healthy controls were com-
pared for age, sex and habits. Detailed clinical and per-
sonal information of each patient was noted in a
standardized proforma. Information regarding the
patients name, age, sex, occupation, personal habits and
present complaints was gathered. Emphasis was given to
addictions like areca nut, tobacco and alcohol. None of
the HNSCC patients gave a history of having OSMF
prior to developing malignancy. Individuals with haema-
tological diseases, previous malignancies, skin diseases
and autoimmune disorders were excluded from the
study. All cases were histopathologically confirmed. The
blood samples were taken after obtaining the patients
informed consent to participate in the study. 5 ml.
blood was drawn from each subject into vacutainer
tubes containing ethylene-di-amine-tetra-acetic acid
(EDTA) and stored at 4°C till the samples were pro-
cessed and isolation of genomic DNA was done.
Isolation of Genomic DNA
Genomic DNA was extracted from the blood samples by
using the Qiagen QIAamp DNA Blood Mini Kit (Qiagen
Inc. USA) The extracted genomic DNA was quantified
and checked for purity by spectrophotometer (Spectro
UV-Vis Double Beam PC, UVD Model 2950
LABOMED, Inc. CA, USA). Ethidium bromide (EtBr)
stained 0.8% agarose gel electrophoresis was used to
confirm the presence of genomic DNA in patient and
controls samples.
Genotyping of the MMP-3 promoter polymorphism
The MMP-3 genotype was determined by the PCR-
RFLP assay. The PCR primers used for amplifying the
MMP-3 polymorphism were: forward primer (FP) 5’-
GGTTCTCCATTCCTTTGATGGGGGGAAAGA-3’
and reverse primer (RP) 5’-CTTCCTGGAATTCACAT-
CACTGCCACCACT-3’ [17]. An A to G mutation at
the second nucleotide close to the 3’ end of the FP was
made to create a Tth111I (TakaRa Biotechnology Co.
Ltd, Dalian, China) recognition site in the case of a 5A
a l l e l e .P C R( M JR e s e a r c hP T C1 0 0 ,G M I ,I n c ,M i n n e -
sota, USA) was performed in a 25 μl volume containing
50 ng of genomic DNA template, 2.5 μl of 10× PCR
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(Fermentas Inc. Glen Burnie MD), 200 nmol of dNTPs
and 200 nmol of forward and reverse primer. The PCR
cycling conditions were 5 min at 94°C followed by 35
cycles of 45 s at 94°C, 45 s at 66°C and 45 s at 72°C and
with a final step at 72°C for 15 min to allow for the
complete extension of all PCR fragments. For a negative
control, each PCR reaction used distilled water instead
of DNA in the reaction mixture.
Restriction enzyme (Tth 111I) digestion of MMP-3 gene
A1 0μl aliquot of PCR product was digested at 65°C for
5h r si na1 5μl reaction containing 10 U of Tth111 I
and 1× reaction buffer. After digestion, the products
were separated on 3.5% agarose gel stained with EtBr.
On electrophoresis, the 5A alleles were represented by
DNA bands of 97 and 32 bp, the 6A alleles were repre-
sented by a DNA band of 129 bp, whereas the heterozy-
gote displayed a combination of both alleles (129, 97
and 32 bp) Fig. 1[A] and 1[B].
Statistical analysis
The Chi-square test (c
2 test) was used to find out the
difference in genotypic distribution of MMP-3 promo-
ters between the OSMF, HNSCC and control groups.
Fisher’s exact test has also been applied in the statistical
analysis. A p-value of < 0.05 was considered as
statistically significant. For each parameter, patients with
OSMF histopathological grade I, II, III, IV and HNSCC,
risk was analyzed by odds ratios (OR) and 95% Confi-
dence Intervals (95% CI). Distributions of MMP-3 geno-
type promoter polymorphisms in OSMF, HNSCC and
control groups were analyzed by the Hardy-Weinberg
equilibrium. The statistical analysis was performed using
the SPSS 15.0 software package (SPSS Japan Inc., Tokyo,
Japan).
Results
Patients of OSMF were diagnosed on the basis of clini-
cal signs including trismus and presence of fibrotic
bands in the oral cavity and malignancies. Figure 2[A, B,
C] and 2[D]. MMP-3 promoter genotypes in patients
with OSMF, HNSCC and controls were analyzed with
respect to gender, age, habits like tobacco consumption
with or without areca nut chewing, alcohol intake, as
well as histopathological grade of OSMF, TNM staging
of HNSCC and the location of the lesion.
Out of 101 patients with OSMF, 74 (73.27%) had 6A/
6A genotype, 24 (23.76%) 5A/6A and 3 (2.97%) 5A/5A,
while in 135 patients with HNSCC, 106 (78.5%) had 6A/
6A genotype, 23 (17.03%) 5A/6A and 6 (4.44%) 5A/5A.
O ft h em a l ep a t i e n t sw i t hO S M F ,6 2h a d6 A / 6 A ,1 4
(5A/6A) and 2 (5A/5A) genotype and of the female
patients, 12 had 6A/6A, 10 (5A/6A) and 1 (5A/5A)
Figure 1 A The expected PCR product size of MMP-3 gene by 100 bp marker [M], Lane 1-7 shows PCR product followed by separation
on 2.0% agarose gel was confirmed; B: Genotyping of MMP-3 Promoter (-1171 5A->6A) Polymorphism by PCR-RFLP analysis followed
by separation on 3. 5% agarose gel, Lane M = 100 bp marker; lane 1, 3, 4, 5 = 5A/6A; lane 2 = 5A/6A; lane 6 = 5A/5A.
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15 (5A/6A) and 5 (5A/5A) genotype and of the females,
12 had 6A/6A, 8 (5A/6A) and 1 (5A/5A) genotype. Ana-
lyzing the different genotypes (6A/6A, 5A/6A and 5A/
5A), it was found that the polymorphic association of
these genotypes was statistically significant in both male
and females suffering from OSMF (p = 0.001) and
HNSCC (p = 0.01), according to the Fisher’se x a c tt e s t .
This conclusion was drawn on analysis of the dataset
illustrated in Table no 1.
Association of 5A/5A, 6A/6A and 5A/6A genotypes
and tobacco chewing with areca nut chewers showed a
significant association in OSMF and HNSCC cases
respectively (p = 0.02,0.003) as did the OSMF (p =
0.001) and HNSCC histopathological grading (p =
0.001) as well as location, both in OSMF and HNSCC
(p = 0.81 and p = 0.59 respectively) [Table 1].
The MMP-3 genotype distinguished homozygous 6A
genotype (6A/6A), homozygous 5A genotype (5A/5A)
and heterozygous genotype (5A/6A). The 5A allele fre-
quencies in OSMF, HNSCC and controls were 0.15, 0.13
and 0.07 respectively (According to Hardy-Weinberg
equilibrium). A significant difference was found in 5A
allele frequency between OSMF and controls (p = 0.01),
as well as HNSCC and controls (p = 0.03). 5A genotype
had a more than two fold risk for OSMF (OR = 2.26) and
little less in HNSCC (OR = 1.94) in relation to the con-
trol group. Frequency of 5A/6A or 5A/5A promoter gen-
otypes having 5A alleles was associated with MMP-3
single nucleotide polymorphism (SNP) in OSMF (5A
allele frequency = 0.15, p = 0.01, OR = 2.26, 95% CI =
1.22-4.20). Similar difference was also found in MMP-3
genotype distribution in HNSCC (5A allele frequency =
0.13, p = 0.03, OR = 1.94, 95% CI 1.06-3.51) as compared
to controls (5A allele frequency = 0.07) [Table 2].
Receiver operating characteristics (ROC) showed a sig-
nificant association between age and MMP-3 genotypes
in OSMF and HNSCC. Figure 3[A] and 3[B] shows that
6A/6A allele was also found to be significant in subjects
both over and under 45 years of age. While, 5A/5A car-
rier alleles showed an association only in patients less
than 45 years of age. Fisher’s exact test also revealed that
patients with 5A alleles had a significant risk to develop
OSMF (p = 0.01, OR = 2.51, 95%CI = 1.27-4.94). [Table 3
and 4]. On the other hand, significant difference was
found in MMP-3 genotype distribution (6A/6A, 5A/5A
Figure 2 Clinical picture of patients with OSMF and HNSCC.
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Page 5 of 9and 5A/6A) between the areca nut with tobacco chewers
a n dt h en o nc h e w e r sb o t hi nO S M F( p=0 . 0 2 )a n d
HNSCC (p = 0.003) patients vis-à-vis control group (p =
0 . 1 2 )[ T a b l e5a n d6 ] .H o w e v e ri ts h o u l db en o t e dt h a t
there are differences in age distribution, smoking and
areca nut chewing between controls and patients.
Discussion
Carcinogenesis is a multistage process, which involves
various molecular mechanisms associated to the funda-
mental alterations in cell physiology such as growth sig-
nals, escape from apoptosis, uncontrolled replication
and growth-inhibitory signals [18]. MMPs are involved
in the degradation of extra cellular matrix (ECM) com-
ponents that take part in several molecular mechanisms
such as invasion, angiogenesis, metastasis and progres-
sion of malignancies. Nagata et al suggested that expres-
sion levels of that molecules which are involved in
tissue remodeling and cell-ECM adhesion, especially
MMP-1 and integrin-3, may provide an accurate bio-
marker diagnosis for predicting the risk of cervical
lymph node metastasis in oral squamous cell carcinoma
(OSCC) [19]. Lin et al reported that functional promoter
polymorphisms of MMP-1 and MMP-2 gene might be
associated with the risk for development of OSCC but
not in OSMF [20,21].
The MMP-3 promoter polymorphism is associated
with a higher MMP-3 transcription level, Hashimoto et
al reported that the MMP-3 SNP was not associated
with the progression of OSCC as reflected by TNM and
advances in stage [9]. In this study, a higher frequency
of 5A allele was found in OSMF and HNSCC as com-
pared to controls. This study supports the hypothesis
that adenine insertion/deletion polymorphism in the
MMP-3 promoter region was associated with the
increased chance of development of OSMF. Tu et al
also earlier reported the similar findings in OSMF
patients from Taiwan [22].
Table 2 The genotype and allele frequency of MMP-3 in OSMF, HNSCC patients and controls.
Groups Total
(N)
5A/5A
Genotype
5A/6A
Genotype
6A/6A
Genotype
5A allele frequency OR 95%CI P-value
Control 126 2 (1.58%) 14 (11.1%) 110 (87.3%) 0.07 1 - -
OSMF 101 3(2.9%) 24 (23.7%) 74 (73.3%) 0.15 2.26 1.22-4.20 0.01
HNSCC 135 6 (4.44%) 23 (17.03%) 106 (78.52%) 0.13 1.94 1.06-3.51 0.03
[OR = Odd Ratio; CI = confidence interval; MMP = matrix metalloproteinase; OSMF = oral submucous fibrosis; HNSCC = Head and neck squamous cell carcinoma]
Figure 3 ROC 6A/6A allele was also found to be significant in
subjects both over and under 45 years of age, while 5A/5A
carrier alleles showed an association only in patients less than
45 years of age in case of [A] OSMF and [B] HNSCC.
Table 3 Univariate analysis of predictive factors in case
of OSMF.
OSMF CONTROL p-value OR 95%CI
Age
<45 76 64 0.001 2.94 1.66-5.21
≥45 25 62
Gender
Male 77 105 0.24 0.64 0.33-1.23
Female 24 21
6A*
-ve 3 2 0.79 1.89 0.05-6.93
+ve 98 124
5A**
-ve 74 110 0.01 2.508 1.27-4.94
+ve 27 16
*6A-denotes 5A/5A genotypes and 6A+denotes 6A/6A or 5A/6A. **: 5A-
denotes 6A/6A genotype and 5A+ denotes 5A/5A or 5A/6A. Data were
analyzed by Fisher’s exact test.
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cavity. OSMF is a premalignant disorder, which can be
induced by areca nut chewing [23]. Due to excess chew-
ing of areca nut; arecoline may increase the production
of collagen fibers in the sub epidermal layer of buccal
cavity and causes fibrosis. Chiu et al reported that areca
chewing as well as polymorphism of genes associated
with collagen homeostasis was correlated with risk of
OSMF [24]. Shin et al suggested that polymorphism of
transforming growth factor (TGF-a) related to an innate
immune response was also found to associated with the
risk of OSMF [25]. In this study, a significant difference
was found in MMP-3 genotype polymorphism between
controls, OSMF and HNSCC patients.
Areca nut chewers having a 5A allele had a higher
risk for OSMF and HNSCC (OR = 2.26 and 1.94
respectively) in relation to the control group. Tu et al
reported a significant difference in MMP-3 genotypic
polymorphism between patients with OSMF vis-à-vis
controls in male areca chewers, however not in
patients with OSCC from Taiwan [22]. On the other
hand, Vairaktaris et al from Greece also reported a sig-
nificant difference in the 5A allele in oral cancer
patients who smoked [26].
T h ep r e s e n c eo ft h e5 Aa l l e l eh a sb e e nr e p o r t e dt o
be associated with susceptibility for oral cancer, lung
carcinoma, esophageal squamous cell carcinoma, head
and neck carcinoma, ovarian cancer as well as breast
carcinomas [22,27-31]. On the other hand, a patient
with lower expression of 6A allele has been associated
with increased risk for colorectal cancer [32]. Nishijima
et al reported that the anti-MMP-3 antibody is a sero-
logical marker that reflects the severity of systemic
sclerosis and also suggested that it may contribute to
the development of fibrosis by inhibiting MMP-3 activ-
ity and reducing the ECM [33]. Murawaki et al 1999
reported that measurement of serum MMP-3 is of lit-
tle use for assessing fibrolysis in chronically diseased
livers [34].
Tissue inhibitors of metalloproteinases (TIMPs) are
the main endogenous inhibitors of the MMPs [35].
Strup-Perrot et al reported that expression of collagens;
MMPs and TIMPs were increased simultaneously due
to effect of collagen deposition in abdominal and pelvic
cancers in radiation enteritis [36]. Chang et al found
that arecoline acted not only as an inhibitor of gelatino-
lytic activity of MMP-2, but also a stimulator for TIMP-
1 activity in OSMF [37]. Their study concluded that
MMPs transcription activity might be associated with
genesis of OSMF in younger areca nut chewers.
In this study, 6A/6A alleles was found to be significant
both in OSMF and HNSCC patients less than and more
than 45 years of age, while 5A/5A carrier alleles showed
Table 4 Univariate analysis of predictive factors in case
of HNSCC.
HNSCC CONTROL p-value OR 95%CI
Age
<45 16 78 0.001 2.74 0.13-0.54
≥45 36 48
Gender
Male 114 105 0.93 1.08 0.56-2.10
Female 21 21
6A*
-ve 6 2 0.03 2.93 0.58.79
+ve 129 126
5A**
-ve 106 110 0.02 1.8 0.96-3.66
+ve 29 16
* 6A-denotes 5A/5A genotypes and 6A+denotes 6A/6A or 5A/6A. **: 5A-
denotes 6A/6A genotype and 5A+ denotes 5A/5A or 5A/6A. Data were
analyzed by Fisher’s exact test.
Table 5 Age and habits distribution in relation to alleles in OSMF and Controls.
Characteristics OSMF
(N = 101)
Control
(N = 126)
6A/6A 5A/6A 5A/5A p-value 5A/5A 6A/6A 5A/6A (p-value)
Age (Yrs)
Mean ± SD 38.8 ± 14.5 37.6 ± 14.2 36 ± 8.5 0.671 17.5 ± 0.7 36.7 ± 12.4 38.8 ± 16 0.41
Tobacco with Areca nut
Chewer 72(97.3%) 23 (95.8%) 2 (66.7%) 0.02 2(100%) 71(64.5%) 12(85.7%) 0.12
Non Chewer 2(2.7%) 1 (4.2%) 1 (33.3%) 0 39(35.5%) 2(14.3%)
Smoking status
Smoker 42(56.7%) 19(79.2%) 3 (100%) 0.077 0 47(42.7%) 4(28.6%) 0.11
Non-smoker 32(43.3%) 5 (20.8%) 0 2(100%) 63(57.3%) 10(71.4%)
Alcohol Intake
Drinker 22(29.7%) 3 (12.5%) 2 (66.7%) 1.16 0 25(22.7%) 1(7.1%) 0.24
Non Drinker 52(70.3%) 21 (87.5%) 1 (33.3%) 2(100%) 85(77.3%) 13(92.9%)
[Data was expressed as mean ± SD and %. Fischer exact test is used for habits in cases and control groups]
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45 years of age. Nishizawa et al reported that apparent
reduction of the MMP-1 1G/1G and 1G/2G genotypes
distribution among the early onset OSCC cases under
the ages of 45 years [38]. Since there were differences in
age distribution, smoking and areca chewing between
control and patients, the result need to be cautiously
interpreted.
McCawley et al reported that high MMP-3 expression
levels in OSCC may play an important role in oncogen-
esis and especially in invasion [39] Vairaktaris et al
reported that the genotype containing 5A allele had a
two-fold risk of oral cancer development in smokers
[26]. In this study, a significant difference was found in
MMP-3 genotypic polymorphism between controls and
HNSCC (OR = 1.94), which is in concordance with
results of Varkataris et al [26].
Conclusions
We conclude that adenosine insertion/deletion poly-
morphism (-1171 5A->6A) in the MMP-3 promoter
region may play an important role in the development,
initiation and progression of these lesions. To the best
of our knowledge, this is the first study dealing with
MMP-3 polymorphism in OSMF and HNSCC patients
of Indian origin. Studies with a larger number of sub-
jects are recommended to elucidate the genetic and
polymorphic contribution of MMPs in these lesions, as
this may have important role in designing future thera-
peutic strategies.
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